ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2011
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trial
- Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis.Blood cancer journal · 2014Trial
- MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Immunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report.Journal of neurological surgery reports · 2024Article
- [Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.Blood advances · 2022Article
- A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.Journal of experimental & clinical cancer research : CR · 2022Article
- Immunoglobulin D-λ/λ biclonal multiple myeloma: A case report.World journal of clinical cases · 2021Article
- Light chain deposition disease involving kidney and liver in a patient with IgD myeloma.BMC nephrology · 2021Article
- Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells.BMJ case reports · 2019Article
- Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.Cancer communications (London, England) · 2019Article
- Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.BMC cancer · 2018Article
- Recent advances in multiple myeloma: a Korean perspective.The Korean journal of internal medicine · 2016Review
- Aggressive FLC Escape in a Patient with IgD Myeloma.Case reports in hematology · 2015Article
- Ophthalmic manifestations of atypical IgD multiple myeloma.BMJ case reports · 2012Article
- IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.Journal of experimental & clinical cancer research : CR · 2012Article
- AL Amyloidosis in a Patient with IgD Myeloma.Indian journal of nephrologyArticle
- Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture.Case reports in oncologyArticle
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the clinical features, outcomes including efficacy of treatment, and prognostic factors of patients with immunoglobulin D multiple myeloma (IgD MM). DESIGN AND
methodsSeventy-five patients diagnosed with IgD MM were selected from the Korean Myeloma Registry database (www.myeloma.or.kr).
resultsMedian age was 57 years and the main presenting features were bone pain (77%). Renal function impairment and hypercalcemia were present in 40 (53%) and 20 (27%) patients. Sixty-seven patients (89%) had lambda light chains. Forty-eight patients (64%) were of stage III by International Staging System. Twenty-six patients (53%) had chromosomal abnormalities mostly by conventional cytogenetics. Thirty-nine patients (54%) were treated with vincristine, adriamycin, and dexamethasone chemotherapy; the overall response rate (ORR) of 56%. Sixteen patients (22%) received first-line chemotherapy including new drugs (bortezomib or thalidomide), with an ORR of 81%. At a median follow-up time of 28.6 months, median overall survival (OS) was 18.5 months. Age, extramedullary plasmacytoma, del(13) or hypoploidy, serum β(2) microglobulin level, and platelet count were significant prognostic factors for OS.
conclusionsIgD MM is an aggressive disease that is usually detected at an advanced stage. Despite a positive initial response, survival after relapse was dismal. Intensive treatment strategies before and following stem cell transplantation may improve outcomes in younger patients.
Indexed as
Identifiers
20682550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.